Claim 70% Off TipRanks Premium
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
CSL ( (AU:CSL) ) has shared an update.
CSL Limited has informed the market that 34,261 conditional rights (security code CSLAL) have lapsed after the performance or vesting conditions attached to them were not satisfied or became incapable of being met, effective 7 January 2026. The cessation of these rights results in a small reduction in potential future issued capital and reflects routine adjustments to CSL’s equity-based incentive structures, with negligible direct impact on the company’s overall capital position but relevance for holders and participants in its share-based remuneration plans.
The most recent analyst rating on (AU:CSL) stock is a Hold with a A$188.00 price target. To see the full list of analyst forecasts on CSL stock, see the AU:CSL Stock Forecast page.
More about CSL
CSL Limited is a global biotechnology company listed on the ASX that develops and manufactures biopharmaceutical products, including vaccines, plasma-derived therapies and other specialty medicines, serving healthcare markets worldwide.
Average Trading Volume: 1,055,176
Technical Sentiment Signal: Sell
Current Market Cap: A$81.65B
Find detailed analytics on CSL stock on TipRanks’ Stock Analysis page.